Latham Group reported a 12.5% increase in third-quarter net sales to $182.2 million, driven by strong growth in in-ground fiberglass pools and autocovers, especially in Florida and Texas. Net income surged 48.5% to $12.1 million despite a one-time $5 million debt refinancing loss. The company raised its full-year sales growth guidance to 11.7% and adjusted EBITDA growth to 15.2%, expecting to outperform the U.S. in-ground pool market in 2027. Additionally, Latham's board approved a $100 million share buyback program, signaling confidence in long-term growth.
Latham Group's third-quarter results show a 48.5% surge in net income, highlighting strong financial performance. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 04, 2026 03:41 WIB: Among 134 priced US stocks, 42 rose and 91 fell. Notable movers include DKS at USD 135.42 with a -4.79% change and a typical hold time of 23 days, JMKE at USD 19.69 with a +4.68% change but 100% sell order activity, and STLA at USD 4.51 down -4.45% with a typical hold time of 5 days.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
